Kumanan Wilson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kumanan Wilson has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Ian D. Graham
Integrated Knowledge Translation Research Network, Ottawa Hospital Research Institute, Ottawa, Canada
5 shared publications Heather Boon
Leslie Dan Faculty of Pharmacy and a Canadian Institutes of Health Research New Investigator
4 shared publications- Christopher Dornan
Carleton University
3 shared publications Maura N Ricketts
3 shared publicationsPaul Ritvo
Division of Preventive Oncology at Cancer Care Ontario, School of Kinesiology and Health Sciences at York University and in the Department of Public Health Sciences at the University of Toronto
3 shared publicationsAlan Tinmouth
Clinical Epidemiology Program, Ottawa Health Research Institute, Ottawa, Ontario, Canada
2 shared publications
Latest Publications
- 1 April 2008
- Published by SAGE Publications in Public Understanding of Science
- Vol. 17 (2) , 231-243
Parental views on pediatric vaccination: the impact of competing advocacy coalitions
The debate on pediatric vaccination policy has been characterized by the presence of two distinct coalitions: those in favor of current vaccination policies and those expressing concern about these policies. The target of these coalitions is the vaccination decision of parents. To determine their influence, we conducted four focus groups in Toronto, Canada examining parental decision-making concerning pediatric vaccination. Our focus groups consisted of both fathers and mothers and parents who fully vaccinated and those who did not. Using the Advocacy Coalition Framework as an analytic guide, we identified several themes that provided insights into how effective the two coalitions have been in conveying their viewpoints. In general, we identified a variety of levels of belief systems existing amongst parents concerned about vaccination, some more amenable to change than others. We found that the choice to not vaccinate was largely a result of concerns about safety and, to a lesser extent, about lack of effectiveness. These parental views reflected the ability of the coalition concerned about vaccination to challenge parents' trust in traditional public health sources of information. In contrast, the parental decision to vaccinate was due to recognizing the importance of preventing disease and also a consequence of not questioning recommendations from public health and physicians and feeling pressured to because of school policies. Importantly, parents who fully vaccinate appear to have weaker belief systems that are potentially susceptible to change. While current policies appear to be effective in encouraging vaccination, if trust in public health falters, many who currently support vaccination may reevaluate their position. More research needs to be conducted to identify approaches to communicate the risks and benefits of vaccination to parents.
- 1 April 2008
- Published by SAGE Publications in Public Understanding of Science
- Vol. 17 (2) , 231-243
Parental views on pediatric vaccination: the impact of competing advocacy coalitions
The debate on pediatric vaccination policy has been characterized by the presence of two distinct coalitions: those in favor of current vaccination policies and those expressing concern about these policies. The target of these coalitions is the vaccination decision of parents. To determine their influence, we conducted four focus groups in Toronto, Canada examining parental decision-making concerning pediatric vaccination. Our focus groups consisted of both fathers and mothers and parents who fully vaccinated and those who did not. Using the Advocacy Coalition Framework as an analytic guide, we identified several themes that provided insights into how effective the two coalitions have been in conveying their viewpoints. In general, we identified a variety of levels of belief systems existing amongst parents concerned about vaccination, some more amenable to change than others. We found that the choice to not vaccinate was largely a result of concerns about safety and, to a lesser extent, about lack of effectiveness. These parental views reflected the ability of the coalition concerned about vaccination to challenge parents' trust in traditional public health sources of information. In contrast, the parental decision to vaccinate was due to recognizing the importance of preventing disease and also a consequence of not questioning recommendations from public health and physicians and feeling pressured to because of school policies. Importantly, parents who fully vaccinate appear to have weaker belief systems that are potentially susceptible to change. While current policies appear to be effective in encouraging vaccination, if trust in public health falters, many who currently support vaccination may reevaluate their position. More research needs to be conducted to identify approaches to communicate the risks and benefits of vaccination to parents.
- Open Access
- 7 March 2008
- Published by Springer Nature in Conflict and Health
- Vol. 2 (1) , 1
Iraq War mortality estimates: A systematic review
Background: In March 2003, the United States invaded Iraq. The subsequent number, rates, and causes of mortality in Iraq resulting from the war remain unclear, despite intense international attention. Understanding mortality estimates from modern warfare, where the majority of casualties are civilian, is of critical importance for public health and protection afforded under international humanitarian law. We aimed to review the studies, reports and counts on Iraqi deaths since the start of the war and assessed their methodological quality and results.Methods: We performed a systematic search of 15 electronic databases from inception to January 2008. In addition, we conducted a non-structured search of 3 other databases, reviewed study reference lists and contacted subject matter experts. We included studies that provided estimates of Iraqi deaths based on primary research over a reported period of time since the invasion. We excluded studies that summarized mortality estimates and combined non-fatal injuries and also studies of specific sub-populations, e.g. under-5 mortality. We calculated crude and cause-specific mortality rates attributable to violence and average deaths per day for each study, where not already provided.Results: Thirteen studies met the eligibility criteria. The studies used a wide range of methodologies, varying from sentinel-data collection to population-based surveys. Studies assessed as the highest quality, those using population-based methods, yielded the highest estimates. Average deaths per day ranged from 48 to 759. The cause-specific mortality rates attributable to violence ranged from 0.64 to 10.25 per 1,000 per year.Conclusion: Our review indicates that, despite varying estimates, the mortality burden of the war and its sequelae on Iraq is large. The use of established epidemiological methods is rare. This review illustrates the pressing need to promote sound epidemiologic approaches to determining mortality estimates and to establish guidelines for policy-makers, the media and the public on how to interpret these estimates.
- 7 March 2008
- Published by Springer Nature in Conflict and Health
- Vol. 2 (1) , 1
Open AccessIraq War mortality estimates: A systematic review
Background: In March 2003, the United States invaded Iraq. The subsequent number, rates, and causes of mortality in Iraq resulting from the war remain unclear, despite intense international attention. Understanding mortality estimates from modern warfare, where the majority of casualties are civilian, is of critical importance for public health and protection afforded under international humanitarian law. We aimed to review the studies, reports and counts on Iraqi deaths since the start of the war and assessed their methodological quality and results.Methods: We performed a systematic search of 15 electronic databases from inception to January 2008. In addition, we conducted a non-structured search of 3 other databases, reviewed study reference lists and contacted subject matter experts. We included studies that provided estimates of Iraqi deaths based on primary research over a reported period of time since the invasion. We excluded studies that summarized mortality estimates and combined non-fatal injuries and also studies of specific sub-populations, e.g. under-5 mortality. We calculated crude and cause-specific mortality rates attributable to violence and average deaths per day for each study, where not already provided.Results: Thirteen studies met the eligibility criteria. The studies used a wide range of methodologies, varying from sentinel-data collection to population-based surveys. Studies assessed as the highest quality, those using population-based methods, yielded the highest estimates. Average deaths per day ranged from 48 to 759. The cause-specific mortality rates attributable to violence ranged from 0.64 to 10.25 per 1,000 per year.Conclusion: Our review indicates that, despite varying estimates, the mortality burden of the war and its sequelae on Iraq is large. The use of established epidemiological methods is rare. This review illustrates the pressing need to promote sound epidemiologic approaches to determining mortality estimates and to establish guidelines for policy-makers, the media and the public on how to interpret these estimates.
- 1 March 2008
- Published by WHO Press in Bulletin of the World Health Organization
- Vol. 86 (3) , 215-220
Strategies for implementing the new International Health Regulations in federal countries
The International Health Regulations (IHR), the principal legal instrument guiding the international management of public health emergencies, have recently undergone an extensive revision process. The revised regulations, referred to as the IHR (2005), were unanimously approved in May 2005 by all Member States of the World Health Assembly (WHA) and came into effect on 15 June 2007. The IHR (2005) reflect a modernization of the international community’s approach to public health and an acknowledgement of the importance of establishing an effective international strategy to manage emergencies that threaten global health security.
- 1 March 2008
- Published by WHO Press in Bulletin of the World Health Organization
- Vol. 86 (3) , 215-220
Strategies for implementing the new International Health Regulations in federal countries
The International Health Regulations (IHR), the principal legal instrument guiding the international management of public health emergencies, have recently undergone an extensive revision process. The revised regulations, referred to as the IHR (2005), were unanimously approved in May 2005 by all Member States of the World Health Assembly (WHA) and came into effect on 15 June 2007. The IHR (2005) reflect a modernization of the international community’s approach to public health and an acknowledgement of the importance of establishing an effective international strategy to manage emergencies that threaten global health security.
- 1 December 2007
- Vol. 53 (12) , 2083-5, 2093
Preserving relationships with antivaccine parents: five suggestions from social psychology.
- 1 December 2007
- Vol. 53 (12) , 2083-5, 2093
Preserving relationships with antivaccine parents: five suggestions from social psychology.
- 20 November 2007
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 177 (11) , 1387-1389
The Krever Commission 10 years later
On Nov. 25, 1997, Justice Horace Krever released his landmark report on how Canada's blood system managed the threat of HIV and hepatitis C transmission from blood transfusions.[1][1] The tainted blood tragedy, as it came to be called, was arguably the largest public health catastrophe in this
- 20 November 2007
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 177 (11) , 1387-1389
The Krever Commission 10 years later
On Nov. 25, 1997, Justice Horace Krever released his landmark report on how Canada's blood system managed the threat of HIV and hepatitis C transmission from blood transfusions.[1][1] The tainted blood tragedy, as it came to be called, was arguably the largest public health catastrophe in this
- Open Access
- 31 July 2007
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 4 (7) , e246
WHO's Response to Global Public Health Threats: XDR-TB
- 31 July 2007
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 4 (7) , e246
Open AccessWHO's Response to Global Public Health Threats: XDR-TB
- Top Cited PapersOpen Access
- 11 December 2006
- Published by Springer Nature in BMC Public Health
- Vol. 6 (1) , 300
Effectiveness of smoking cessation therapies: a systematic review and meta-analysis
Background: Smoking remains the leading preventable cause of premature deaths. Several pharmacological interventions now exist to aid smokers in cessation. These include Nicotine Replacement Therapy [NRT], bupropion, and varenicline. We aimed to assess their relative efficacy in smoking cessation by conducting a systematic review and meta-analysis. Methods: We searched 10 electronic medical databases (inception to Sept. 2006) and bibliographies of published reviews. We selected randomized controlled trials [RCTs] evaluating interventions for smoking cessation at 1 year, through chemical confirmation. Our primary endpoint was smoking cessation at 1 year. Secondary endpoints included short-term smoking cessation (~3 months) and adverse events. We conducted random-effects meta-analysis and meta-regression. We compared treatment effects across interventions using head-to-head trials and when these did not exist, we calculated indirect comparisons. Results: We identified 70 trials of NRT versus control at 1 year, Odds Ratio [OR] 1.71, 95% Confidence Interval [CI], 1.55–1.88, P =< 0.0001). This was consistent when examining all placebo-controlled trials (49 RCTs, OR 1.78, 95% CI, 1.60–1.99), NRT gum (OR 1.60, 95% CI, 1.37–1.86) or patch (OR 1.63, 95% CI, 1.41–1.89). NRT also reduced smoking at 3 months (OR 1.98, 95% CI, 1.77–2.21). Bupropion trials were superior to controls at 1 year (12 RCTs, OR1.56, 95% CI, 1.10–2.21, P = 0.01) and at 3 months (OR 2.13, 95% CI, 1.72–2.64). Two RCTs evaluated the superiority of bupropion versus NRT at 1 year (OR 1.14, 95% CI, 0.20–6.42). Varenicline was superior to placebo at 1 year (4 RCTs, OR 2.96, 95% CI, 2.12–4.12, P =< 0.0001) and also at approximately 3 months (OR 3.75, 95% CI, 2.65–5.30). Three RCTs evaluated the effectiveness of varenicline versus bupropion at 1 year (OR 1.58, 95% CI, 1.22–2.05) and at approximately 3 months (OR 1.61, 95% CI, 1.16–2.21). Using indirect comparisons, varenicline was superior to NRT when compared to placebo controls (OR 1.66, 95% CI 1.17–2.36, P = 0.004) or to all controls at 1 year (OR 1.73, 95% CI 1.22–2.45, P = 0.001). This was also the case for 3-month data. Adverse events were not systematically different across studies. Conclusion: NRT, bupropion and varenicline all provide therapeutic effects in assisting with smoking cessation. Direct and indirect comparisons identify a hierarchy of effectiveness.
- 11 December 2006
- Published by Springer Nature in BMC Public Health
- Vol. 6 (1) , 300
Top Cited PapersOpen AccessEffectiveness of smoking cessation therapies: a systematic review and meta-analysis
Background: Smoking remains the leading preventable cause of premature deaths. Several pharmacological interventions now exist to aid smokers in cessation. These include Nicotine Replacement Therapy [NRT], bupropion, and varenicline. We aimed to assess their relative efficacy in smoking cessation by conducting a systematic review and meta-analysis. Methods: We searched 10 electronic medical databases (inception to Sept. 2006) and bibliographies of published reviews. We selected randomized controlled trials [RCTs] evaluating interventions for smoking cessation at 1 year, through chemical confirmation. Our primary endpoint was smoking cessation at 1 year. Secondary endpoints included short-term smoking cessation (~3 months) and adverse events. We conducted random-effects meta-analysis and meta-regression. We compared treatment effects across interventions using head-to-head trials and when these did not exist, we calculated indirect comparisons. Results: We identified 70 trials of NRT versus control at 1 year, Odds Ratio [OR] 1.71, 95% Confidence Interval [CI], 1.55–1.88, P =< 0.0001). This was consistent when examining all placebo-controlled trials (49 RCTs, OR 1.78, 95% CI, 1.60–1.99), NRT gum (OR 1.60, 95% CI, 1.37–1.86) or patch (OR 1.63, 95% CI, 1.41–1.89). NRT also reduced smoking at 3 months (OR 1.98, 95% CI, 1.77–2.21). Bupropion trials were superior to controls at 1 year (12 RCTs, OR1.56, 95% CI, 1.10–2.21, P = 0.01) and at 3 months (OR 2.13, 95% CI, 1.72–2.64). Two RCTs evaluated the superiority of bupropion versus NRT at 1 year (OR 1.14, 95% CI, 0.20–6.42). Varenicline was superior to placebo at 1 year (4 RCTs, OR 2.96, 95% CI, 2.12–4.12, P =< 0.0001) and also at approximately 3 months (OR 3.75, 95% CI, 2.65–5.30). Three RCTs evaluated the effectiveness of varenicline versus bupropion at 1 year (OR 1.58, 95% CI, 1.22–2.05) and at approximately 3 months (OR 1.61, 95% CI, 1.16–2.21). Using indirect comparisons, varenicline was superior to NRT when compared to placebo controls (OR 1.66, 95% CI 1.17–2.36, P = 0.004) or to all controls at 1 year (OR 1.73, 95% CI 1.22–2.45, P = 0.001). This was also the case for 3-month data. Adverse events were not systematically different across studies. Conclusion: NRT, bupropion and varenicline all provide therapeutic effects in assisting with smoking cessation. Direct and indirect comparisons identify a hierarchy of effectiveness.
- 1 December 2006
- Published by Elsevier in The Lancet
- Vol. 368 (9552) , 2037-2039
A third episode of transfusion-derived vCJD
- 1 December 2006
- Published by Elsevier in The Lancet
- Vol. 368 (9552) , 2037-2039
A third episode of transfusion-derived vCJD
- 15 November 2006
- Published by Longwoods Publishing in Healthcare Policy
- Vol. 2 (2) , 35-42
Pandemic Threats and the Need for New Emergency Public Health Legislation in Canada
Is Canada prepared to manage a pandemic threat within its borders ? The outbreak of SARS in exposed some of the limitations of this country ' s abilities in this
- 15 November 2006
- Published by Longwoods Publishing in Healthcare Policy
- Vol. 2 (2) , 35-42
Pandemic Threats and the Need for New Emergency Public Health Legislation in Canada
Is Canada prepared to manage a pandemic threat within its borders ? The outbreak of SARS in exposed some of the limitations of this country ' s abilities in this
- 2 October 2006
- Published by Elsevier in Social Science & Medicine
- Vol. 64 (1) , 174-185
Variant Creutzfeldt–Jakob disease and the Canadian blood system after the tainted blood tragedy
- 2 October 2006
- Published by Elsevier in Social Science & Medicine
- Vol. 64 (1) , 174-185
Variant Creutzfeldt–Jakob disease and the Canadian blood system after the tainted blood tragedy